ADVENT at EAPS 2024

The ADVENT program will present a symposium to discuss diagnosis, pathophysiology, comorbidities of atopic dermatitis in children, as well as emerging treatment options for management of atopic dermatitis (AD) in children, who are candidates for systemic therapy at the 2024 European Academy of Paediatric Societies (EAPS) Congress.

Perla Lansang +2 more

See post-event materials

Past event

17October2024

Location

Austria Center Vienna

Bruno-Kreisky-Platz 1, 1220 Wien, Austria 1010 Vienna Austria

Symposium Details

October 19

Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

See On-Demand materials

Location

Austria Center Vienna

Bruno-Kreisky-Platz 1, 1220 Wien, Austria 1010 Vienna Austria

Speakers

Dermatology

Perla Lansang

The Hospital for Sick Children Toronto, Canada

Dermatology

Christine Bangert

Medical University of Vienna General Hospital, Vienna, Austria

Allergy/Immunology

Mark Boguniewicz

Professor in the Division of Allergy-Immunology, National Jewish Health and University of Colorado School of Medicine, United States

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region